Xenon Pharmaceuticals XENE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's operating income?
- Xenon Pharmaceuticals (XENE) reported operating income of -$112.33M in Q1 2026.
- How has Xenon Pharmaceuticals's operating income changed year-over-year?
- Xenon Pharmaceuticals's operating income decreased by 54.4% year-over-year, from -$72.74M to -$112.33M.
- What is the long-term trend for Xenon Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's operating income has grown at a 47.4% compound annual growth rate (CAGR), from -$78.99M to -$373.07M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.